Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADILWNASDAQ:BFRIWNASDAQ:LBPSWNASDAQ:LIXTW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADILWAdial Pharmaceuticals, Inc. WT EXP 073123$0.00-57.1%$0.00$0.00▼$0.20N/AN/A7,487 shs5,100 shsBFRIWBiofrontera$0.09$0.08$0.02▼$0.26N/AN/A15,179 shsN/ALBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/ALIXTWLixte Biotechnology$0.02-12.1%$0.03$0.02▼$0.09N/AN/A5,228 shs1,040 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADILWAdial Pharmaceuticals, Inc. WT EXP 0731230.00%0.00%0.00%0.00%0.00%BFRIWBiofrontera0.00%-14.63%-10.52%-3.50%+102.22%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%LIXTWLixte Biotechnology0.00%-23.65%-42.78%-35.06%-67.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADILWAdial Pharmaceuticals, Inc. WT EXP 073123N/AN/AN/AN/AN/AN/AN/AN/ABFRIWBiofronteraN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADILWAdial Pharmaceuticals, Inc. WT EXP 073123 0.00N/AN/AN/ABFRIWBiofrontera 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/ALIXTWLixte Biotechnology 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADILWAdial Pharmaceuticals, Inc. WT EXP 073123N/AN/AN/AN/AN/AN/ABFRIWBiofrontera$38.00MN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADILWAdial Pharmaceuticals, Inc. WT EXP 073123N/AN/A0.00∞N/AN/AN/AN/AN/ABFRIWBiofronteraN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADILWAdial Pharmaceuticals, Inc. WT EXP 073123N/AN/AN/AN/AN/ABFRIWBiofronteraN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/ALIXTWLixte BiotechnologyN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADILWAdial Pharmaceuticals, Inc. WT EXP 073123N/ABFRIWBiofronteraN/ALBPSW4D pharmaN/ALIXTWLixte BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipADILWAdial Pharmaceuticals, Inc. WT EXP 073123N/ABFRIWBiofronteraN/ALBPSW4D pharmaN/ALIXTWLixte BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADILWAdial Pharmaceuticals, Inc. WT EXP 07312320N/AN/ANot OptionableBFRIWBiofrontera70N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableLIXTWLixte Biotechnology4N/AN/ANot OptionableLIXTW, LBPSW, ADILW, and BFRIW HeadlinesRecent News About These CompaniesLixte Biotechnology announces closing of $1.05M registered direct offeringFebruary 13, 2025 | markets.businessinsider.comLixte Biotechnology Holdings Inc (LIXT) Stock: More Robust Than the Numbers Suggest?October 31, 2024 | bovnews.comNEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESMarch 27, 2024 | finance.yahoo.comProfessor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchFebruary 27, 2024 | finance.yahoo.comLixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCIFebruary 26, 2024 | finanznachrichten.deLixte CEO Takes On a New CourseFebruary 5, 2024 | labusinessjournal.comLixte Biotechnology Holdings Inc (LIXT)February 1, 2024 | uk.investing.comLIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachOctober 9, 2023 | finance.yahoo.comLixte Biotechnology Holdings, Inc.: LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerSeptember 26, 2023 | finanznachrichten.deLIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerSeptember 20, 2023 | finance.yahoo.comMedia Sentiment Over TimeLIXTW, LBPSW, ADILW, and BFRIW Company DescriptionsAdial Pharmaceuticals, Inc. WT EXP 073123 NASDAQ:ADILWadial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.Biofrontera NASDAQ:BFRIW$0.09 0.00 (0.00%) As of 06/18/2025Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.Lixte Biotechnology NASDAQ:LIXTW$0.02 0.00 (-12.06%) As of 06/18/2025 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
